De Novo · Granted
GrantedCuretis Unyvero LRT Application
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Curetis GmbH · QBH Lower Respiratory Microbial Nucleic Acid Detection System
Granted on Apr 3, 2018 as a new device type through De Novo after a 204-day review. 4 later devices descend from it.
- Decided
- Apr 3, 2018
- Review
- 204 days
- Class
- Class II
- Product code
- QBH
- Recalls
- None
4 later devices descend from it, 2 citing it directly.
- This deviceDEN170047 Curetis Unyvero LRT ApplicationCuretis GmbH · 2018
- Descendant · cites it directly · 2 of its ownK180966 FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2018 · Recalled
- Descendant · 2 generations on · 1 of its ownK212727 FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2021 · Recalled
- Descendant · 3 generations on · 0 of its ownK243222 BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel)…Biofire Diagnostics, LLC (Biomerieux) · 2024 · Recalled
- Descendant · cites it directly · 0 of its ownK191967 Unyvero LRT BAL ApplicationCuretis GmbH · 2019
Most influential descendants
Showing 4 of 4 · See all- K180966FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2018 · cites it directly2descendants
- K212727FilmArray Pneumonia PanelBiofire Diagnostics, LLC · 2021 · 2 generations on1descendant
- K243222BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE® FILMARRAY®…Biofire Diagnostics, LLC (Biomerieux) · 2024 · 3 generations on0descendants
- K191967Unyvero LRT BAL ApplicationCuretis GmbH · 2019 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| 0 (this device) | DEN170047 | Curetis Unyvero LRT Application | Curetis GmbH | 2018 | — |
| +1 | K180966 | FilmArray Pneumonia Panel | Biofire Diagnostics, LLC | 2018 | 4 |
| +2 | K212727 | FilmArray Pneumonia Panel | Biofire Diagnostics, LLC | 2021 | 1 |
| +3 | K243222 | BIOFIRE® FILMARRAY® Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE®… | Biofire Diagnostics, LLC (Biomerieux) | 2024 | 3 |
| +1 | K191967 | Unyvero LRT BAL Application | Curetis GmbH | 2019 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2018 | 1 | 0 |
| 2019 | 1 | 0 |
| 2021 | 1 | 0 |
| 2024 | 1 | 0 |
Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in QBH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
Does it have a predicate?
De Novo decisions do not claim a predicate device.
What descends from it? (4)
2 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Of its descendants, K180966 (Biofire Diagnostics, LLC, 2018) has gone furthest, with 2 descendants of its own.
How does its category compare?
All QBH devicesQBH Lower Respiratory Microbial Nucleic Acid Detection System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.
FDA decisions per year · QBH
1in 2019
2026 to Oct 25, outlined.
Median 510(k) review, days · QBH
Too few QBH 510(k)s in any year since 2007 to give a median.
Recalls per year · QBH
1in 2023
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · QBH
No MAUDE report names QBH since 2007.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 1 | — | 0 | 0 |
| 2019 | 1 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 1 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Unyvero LRT Application is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of nucleic acid sequences from the following microorganisms and antibiotic resistance markers in endotracheal aspirates from adult hospitalized patients with suspected lower respiratory tract infections. Microorganism — Associated antibiotic resistance marker Acinetobacter spp.ᵃ — ctx-Mᵇ, kpc, ndm, oxa-23, oxa-24, oxa-58…
Read the full statement (453 words)
The Unyvero LRT Application is a qualitative nucleic acid multiplex test intended for the simultaneous detection and identification of nucleic acid sequences from the following microorganisms and antibiotic resistance markers in endotracheal aspirates from adult hospitalized patients with suspected lower respiratory tract infections.
Microorganism — Associated antibiotic resistance marker
Acinetobacter spp.ᵃ — ctx-Mᵇ, kpc, ndm, oxa-23, oxa-24, oxa-58, vim
Chlamydia pneumoniae —
Citrobacter freundii — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Enterobacter cloacae complexᶜ — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Escherichia coli — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Haemophilus influenzae — tem
Klebsiella oxytoca — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Klebsiella pneumoniaeᵈ — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Klebsiella variicola — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Legionella pneumophila —
Moraxella catarrhalis —
Morganella morganii — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Mycoplasma pneumoniae —
Proteus spp.ᵉ — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Pseudomonas aeruginosa — ctx-Mᵇ, kpc, ndm, vim
Serratia marcescens — ctx-Mᵇ, kpc, ndm, oxa-48, vim
Staphylococcus aureus — mecA
Stenotrophomonas maltophilia —
Streptococcus pneumoniae —
ᵃ Acinetobacter spp. includes: A. baumannii, A. calcoaceticus, A. haemolyticus, A. junii, A. lwoffii, A. nosocomialis, A. parvus, A. pittii, (detected by LRT Application) and A. ursingii (not detected by LRT Application).
ᵇ ctx-M1 subgroup.
ᶜ Enterobacter cloacae complex includes: E. asburiae, E. cloacae, E. hormaechei, E. kobei, E. ludwigii, and E. xiangfangensis.
ᵈ Klebsiella pneumoniae includes two variants: K. pneumoniae (variant 1), and K. quasipneumoniae (variant 2)
ᵉ Proteus spp. includes P. hauseri, P. mirabilis, P. penneri and P. vulgaris.
The Unyvero LRT Application performed on the Unyvero System is indicated as an aid in the diagnosis of lower respiratory tract infection in adult hospitalized patients with signs and symptoms of lower respiratory infection; results should be used in conjunction with other clinical and laboratory findings. As tracheal aspirates commonly contain colonizing microorganisms, detection of Unyvero LRT microbial targets does not indicate that the microorganism is the cause of the disease. Unyvero positive results do not rule out co-infection with microorganisms not detected by the Unyvero LRT Application. Negative results do not preclude lower respiratory infection, as the causative agent may be a microorganism not detected by this test.
A negative result for any antibiotic resistance marker does not indicate that detected microorganisms are susceptible to applicable antimicrobial agents. Detected resistance markers cannot be definitively linked to specific microorganisms, and may be present in organisms that are not detected by the Unyvero LRT Application such as organisms present as colonizing or normal flora.
Microbiology cultures of aspirates should be performed to obtain isolates for species identification and antimicrobial susceptibility testing, to differentiate quantities of identified microorganisms as well as normal flora present in the specimen and to identify potential microorganisms not targeted by the Unyvero LRT Application.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/DEN170047 · printed Nov 6, 2026
Cite this page
510(k) Report. “DEN170047: Curetis Unyvero LRT Application.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN170047
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026